Abstract 2056P
Background
The wider availability of oncological treatment and the improved survival of cancer patients have increased the frequency of emergency consultations and their impact on healthcare. The aim of this study was to investigate the variables that influence hospital admission, re-consultation and clinical outcomes among oncology patients who seek emergency care.
Methods
Single-center, observational and prospective study. We analyzed a sample of 554 oncology patients who consulted in the Emergency Deparment during regular office hours between March-22 and March-23. Statistics: Chi-squared test to assess association between variables. Kaplan-Meier curves and log-rank test for survival analysis. Significance level: p-value <=0.05.
Results
The baseline characteristics of the study participants were: 50.2% females, 21.5% lung cancer, 68.8% stage IV, 25.8% consulted for digestive symptoms, 37% were hospitalized and 16.4% reconsulted in the following 15 days. The overall median survival was 54 weeks. Factors that were associated with a higher likelihood of hospitalization were lung cancer (26.9% of admissions), stage IV (80.7%), monotherapy chemotherapy (CT) (36.3%), first-line treatment for metastatic disease (40.9%), ECOG 2 (36.8%), digestive symptoms as reason for consultation (29.2%) and complications secondary to the tumor itself as definitive diagnosis (32.2%). Factors significantly associated with a higher likelihood of reconsultation within the following 15 days were lung cancer (19.3% of reconsultations), monotherapy CT (38.6%), ECOG 1 (42.1%) and infectious pathology and complications secondary to the tumor itself (28.1% each one). Factors significantly associated with lower overall survival were hospital admission (median: 16 weeks, 95% CI 3.7-28.2), diagnosis of complications secondary to the tumor itself (median: 11 weeks, 95% CI 10.3 - 23.6) and reconsultation (median: 17 weeks, 95% CI 10.3-23.6).
Conclusions
Among oncology patients admitted to the Emergency department, complications secondary to the underlying oncological disease represent the most relevant variable in the field of oncological emergencies due to their impact on the likelihood of hospitalization, reconsultation and survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Sanchez Canovas: Financial Interests, Personal, Speaker, Consultant, Advisor: Leo Pharma, Sanofi, Lundbeck, Angelini. M.A. Ivars: Financial Interests, Personal, Speaker, Consultant, Advisor: Ipsen Pharma, Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
2045P - Patient Reported Outcome Measures (PROMs) capturing therapy adherence of cancer patients: A systematic literature review
Presenter: Luise Richter
Session: Poster session 06
2046P - The importance of communicating bad news in medical education
Presenter: Georgios Goumas
Session: Poster session 06
2047P - Neutrop: A descriptive, observational study for G-CSF prescription in daily practice
Presenter: Florian Scotté
Session: Poster session 06
2048P - Frequency and clinical relevance of drug-drug interactions with oxycodone among patients with cancer
Presenter: Lotte Hulskotte
Session: Poster session 06
2049P - Osimertinib-related muscle cramps as a common adverse event: A real-world data analysis in the post-approval setting
Presenter: Gisele Moreira
Session: Poster session 06
2050P - Integrating ayurveda herbs with standard of care for management of cancer or cancer treatment related anorexia
Presenter: Yogesh Bendale
Session: Poster session 06
2051P - E-PRO within comprehensive companion program for patients undergoing systemic cancer treatment to reduce emergency visits and inpatient admission in a Peruvian institution
Presenter: Patricia Rioja Viera
Session: Poster session 06
2052P - Adverse events in FLOT chemotherapy for locally advanced gastric cancer: An observational study of pre- and post-operative toxicity profiles
Presenter: Camila Oliveira
Session: Poster session 06
2053P - Dehospitalization through outpatient drug release in clinical pharmacy as a strategic cost-minimization action in a public oncology hospital in the Eastern Amazon: A quantitative analysis
Presenter: Kalysta Borges
Session: Poster session 06
2054P - Metastatic cancer patients hospitalized at initial diagnosis: When does rescue systemic therapy make sense? ONIRIS - A national, prospective study
Presenter: Colin Vercueil
Session: Poster session 06